Knightsbridge Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$822K Buy
5,383
+1,059
+24% +$162K 0.11% 96
2025
Q4
$596K Buy
4,324
+219
+5% +$28.7K 0.1% 96
2025
Q3
$526K Sell
4,105
-145
-3% -$17.7K 0.09% 93
2025
Q2
$514K Buy
4,250
+576
+16% +$64.9K 0.11% 87
2025
Q1
$410K Sell
3,674
-177
-5% -$18.8K 0.11% 92
2024
Q4
$375K Buy
3,851
+457
+13% +$48.7K 0.09% 96
2024
Q3
$390K Buy
3,394
+240
+8% +$27.2K 0.09% 92
2024
Q2
$336K Buy
3,154
+713
+29% +$71.6K 0.08% 93
2024
Q1
$247K Hold
2,441
0.07% 105
2023
Q4
$247K Buy
+2,441
New +$236K 0.07% 105
2023
Q2
Sell
-2,636
Closed -$243K 121
2023
Q1
$243K Sell
2,636
-64
-2% -$5.59K 0.04% 119
2022
Q4
$245K Buy
+2,700
New +$227K 0.05% 120

Other funds holding NVS

Knightsbridge Asset Management's NVS Position: Q1 2026 in Review

Knightsbridge Asset Management increased its Novartis (NVS) stake by 24% in Q1 2026, buying an estimated $162K and bringing the position to 5,383 shares worth $822K. The position accounts for 0.11% of the portfolio, ranked #96.

Knightsbridge Asset Management first reported a position in NVS in Q4 2022 and has held it in 12 quarters since. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Knightsbridge Asset Management held 5,383 shares of Novartis worth $822K as of Q1 2026.
  • Knightsbridge Asset Management bought 1,059 Novartis shares in Q1 2026, an estimated $162K.
  • Novartis made up 0.11% of Knightsbridge Asset Management's portfolio in Q1 2026, its #96 holding.
  • Knightsbridge Asset Management first reported a position in Novartis in Q4 2022 and has held it in 12 quarters since.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Knightsbridge Asset Management's 13F filing for Q1 2026, filed 15 May 2026.